Bills have been introduced in the House and Senate to bar “foreign adversary biotech companies of concern” from doing business with federally funded medical providers.
Biotechnology promises to revolutionize everyday life, with scientists and researchers using it to make rapid advances in medical treatment, genetic engineering in agriculture and novel biomaterials.
The debate over biotechnology is taking place as the Biden administration tries to stabilize the volatile U.S.-China relationship, which has been battered by a range of issues, including a trade war, the COVID-19 pandemic, cybersecurity and militarization in the South China Sea.
The Biden administration has put forward a “whole-of-government approach” to advance biotechnology and biomanufacturing that is important for health, climate change, energy, food security, agriculture and supply chain resilience.
“Both the Chinese government and the Americans have identified biotech as an area important for investment, a sector that presents an opportunity to grow their economy,” said Tom Bollyky, the Bloomberg chair in global health at the Council on Foreign Relations.
What concerns Anna Puglisi, a senior fellow at Georgetown University’s Center for Security and Emerging Technology, is Beijing’s lack of transparency and its unfair market practices.
Puglisi described BGI, a major Chinese biotech company identified in both the House and Senate bills, as “a national champion” that is subsidized and given favored treatment by the state in a system that “blurs private and public as well as civilian and military.”
The original article contains 1,144 words, the summary contains 208 words. Saved 82%. I’m a bot and I’m open source!
This is the best summary I could come up with:
Biotechnology promises to revolutionize everyday life, with scientists and researchers using it to make rapid advances in medical treatment, genetic engineering in agriculture and novel biomaterials.
The debate over biotechnology is taking place as the Biden administration tries to stabilize the volatile U.S.-China relationship, which has been battered by a range of issues, including a trade war, the COVID-19 pandemic, cybersecurity and militarization in the South China Sea.
The Biden administration has put forward a “whole-of-government approach” to advance biotechnology and biomanufacturing that is important for health, climate change, energy, food security, agriculture and supply chain resilience.
“Both the Chinese government and the Americans have identified biotech as an area important for investment, a sector that presents an opportunity to grow their economy,” said Tom Bollyky, the Bloomberg chair in global health at the Council on Foreign Relations.
What concerns Anna Puglisi, a senior fellow at Georgetown University’s Center for Security and Emerging Technology, is Beijing’s lack of transparency and its unfair market practices.
Puglisi described BGI, a major Chinese biotech company identified in both the House and Senate bills, as “a national champion” that is subsidized and given favored treatment by the state in a system that “blurs private and public as well as civilian and military.”
The original article contains 1,144 words, the summary contains 208 words. Saved 82%. I’m a bot and I’m open source!